

**PHARMACEUTICAL COMPOSITION, COMPRISING HUMAN HYALURONIDASE
PH20 VARIANT AND DRUG, FOR SUBCUTANEOUS INJECTION**

【ABSTRACT】

5 The present disclosure relates to a pharmaceutical composition including (a) a drug and (b) a human PH20 variant.

10 The human PH20 variant included in the pharmaceutical composition according to the present disclosure includes amino acid residue substitution (s) in one or more regions selected from an alpha-helix 8 region (S347 to C381) and a linker region (A333 to R346) between alpha-helix 7 and alpha-helix 8 in wild-type human PH20 having the amino acid sequence of SEQ ID NO: 1, wherein amino acid residue (s) located at the N-terminus or the C-terminus is(are) selectively cleaved. In addition, the pharmaceutical composition according to the present disclosure may further include a pharmaceutically acceptable additive, particularly a stabilizer.

20 The pharmaceutical composition according to the present disclosure can maximize the therapeutic effect of a drug used in combination therewith, due to the effect of human PH20 variants.

25 [Figure 20]